gms | German Medical Science

104. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft e. V. (DOG)

21. - 24.09.2006, Berlin

Permanent keratoprosthesis: Improved retention and host/ device interface stability with the newly-modified Boston Keratoprosthesis

Meeting Abstract

Suche in Medline nach

  • K. C. Sippel - Cornea Consultants, Boston, USA
  • J. Aquavella - University of Rochester Eye Institute, Rochester, USA
  • C. H. Dohlman - Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, USA

Deutsche Ophthalmologische Gesellschaft e.V.. 104. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft (DOG). Berlin, 21.-24.09.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06dogDO.12.08

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 18. September 2006

© 2006 Sippel et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.




Long-term retention and host/ device interface stability are the most fundamental requirements for a successful permanent keratoprosthesis. The purpose of this study is to assess the retention rate and stability of a newly-modified model of the Boston Keratoprosthesis (previously known as the Dohlman-Doane Keratoprosthesis).


The surgical results and clinical follow-up of 173 consecutive patients implanted with the updated model of the Boston Keratoprosthesis as treatment for loss of corneal transparency associated with repeated corneal transplant failures were reviewed. This version of the keratoprosthesis has been available only for the past 36 months. Its enhancements include a Rev C design as well as a titanium locking ring to prevent spontaneous loosening of the back plate of the keratoprosthesis, a situation that had occurred on occasion with older models and required surgical revision to repair. Patients with end-stage autoimmune conditions (such as Stevens-Johnson syndrome and ocular cicatricial pemphigoid), as well as patients with severe chemical injury, were excluded from the study; these patients require an alternate surgical technique that is the subject of another study.


Follow-up ranged from 1 to 36 months. No patients required removal of the device. Only two patients required surgical revision of the keratoprosthesis for repair of localized melting at the host/ device interface; these two patients suffered from an underlying autoimmune disorder not diagnosed prior to surgery. Visual results, as expected, were varied and were principally dependent on the underlying visual potential of the eye from a retinal/ optic nerve stand-point.


The newly-modified model of the Boston Keratoprosthesis demonstrates excellent retention and host/ device interface stability over a medium-term follow-up period.